|Articles|December 14, 2022
PHASTAR Joins Oncology Development Program (ODP2)
Targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets.
Advertisement
PHASTAR, has joined Lean Life Science’s Oncology Development Program (ODP2). The targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.
Read more about the program
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
SCOPE Summit 2026 Panel Discussion: Diversity in Clinical Trials—What’s Working, What’s Next
2
SCOPE Summit 2026 Keynote Panel: Is Radical Acceleration in Clinical Research Possible?
3
SCOPE Summit 2026: Reducing Patient Burden Is the Foundation of Wearable Success in Oncology
4
SCOPE Summit 2026: Elevating Patient Experience in Clinical Operations
5